The evaluation of differential renal function in children with renal anomalies typically involves various imaging techniques, including nuclear medicine renal scans (specifically MAG3 and DMSA scans), renal ultrasounds (US), and voiding cystourethrography (VCUG). In an effort to analyze the trends in utilization and costs associated with these imaging modalities over time, we conducted a study using the Merative™ Marketscan® Commercial Database, focusing on data from 2007 to 2021. Our research specifically targeted a cohort of patients aged 0 to 18 years who were diagnosed with renal anomalies such as hydronephrosis, vesicoureteral reflux (VUR), posterior urethral valve (PUV), pyelonephritis, and various forms of obstruction in the urinary tract. Upon reviewing the data, we identified a total of 1,769 unique patients, predominantly between the ages of 0-5 years and comprising 54.95% females. Among the diagnoses, hydronephrosis was the most prevalent, affecting 55.46% of patients, followed by VUR in 32.96% and other specified renal disorders. When analyzing the utilization rates, we found that a small percentage of patients underwent DMSA scans (less than 5%), while MAG3 scans were utilized by 7.87%. In contrast, renal ultrasounds were the most frequently performed imaging procedure, accounting for 63.39% of cases, and VCUGs were conducted in 26.99% of patients. Notably, the average cost associated with renal US was significantly lower than that of MAG3 and DMSA scans. This comprehensive analysis sheds light on the utilization patterns and financial implications of various imaging modalities for renal anomalies in pediatric patients, thereby setting the stage for future epidemiological studies aimed at understanding the ongoing trends in this area.
November 4, 2024
